ArticleCardiovascular engineering and technology2014
Cardiac fibroblast-derived 3D extracellular matrix seeded with mesenchymal stem cells as a novel device to transfer cells to the ischemic myocardium.
Article in Cardiovascular engineering and technology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- RPE-derived extracellular matrix improves graft retention and photoreceptor preservation in preclinical models of retinal degeneration.Matrix biology plus · 2026Article
- Primary Human Cell-Derived Extracellular Matrix from Decellularized Fibroblast Microtissues with Tissue-Dependent Composition and Microstructure.Cellular and molecular bioengineering · 2024Article
- Review
- Regenerative loss in the animal kingdom as viewed from the mouse digit tip and heart.Developmental biology · 2024Review
- Article
- Detergent-Based Decellularization for Anisotropic Cardiac-Specific Extracellular Matrix Scaffold Generation.Biomimetics (Basel, Switzerland) · 2023Article
- Cell-based therapy to boost right ventricular function and cardiovascular performance in hypoplastic left heart syndrome: Current approaches and future directions.Seminars in perinatology · 2023Review
- Advances in the design, generation, and application of tissue-engineered myocardial equivalents.Frontiers in bioengineering and biotechnology · 2023Review
- Decellularized Extracellular Matrix Scaffolds for Cardiovascular Tissue Engineering: Current Techniques and Challenges.International journal of molecular sciences · 2022Review
- Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study.American heart journal plus : cardiology research and practice · 2022Review
- Effect of Decellularized Extracellular Matrix Bioscaffolds Derived from Fibroblasts on Skin Wound Healing and Remodeling.Frontiers in bioengineering and biotechnology · 2022Article
- Developmental lineage of human pluripotent stem cell-derived cardiac fibroblasts affects their functional phenotype.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Cultured cardiac fibroblasts and myofibroblasts express Sushi Containing Domain 2 and assemble a unique fibronectin rich matrix.Experimental cell research · 2021Article
- Cardiac Fibroblasts and Myocardial Regeneration.Frontiers in bioengineering and biotechnology · 2021Review
- Cardiac fibroblast derived matrix-educated macrophages express VEGF and IL-6, and recruit mesenchymal stromal cells.Journal of immunology and regenerative medicine · 2020Article
- Mapping current research and identifying hotspots on mesenchymal stem cells in cardiovascular disease.Stem cell research & therapy · 2020Article
- Cell-derived extracellular matrix-coated silk fibroin scaffold for cardiogenesis of brown adipose stem cells through modulation of TGF-β pathway.Regenerative biomaterials · 2020Article
- Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine.Stem cell research · 2020Review
- Cell-Derived Extracellular Matrix for Tissue Engineering and Regenerative Medicine.Frontiers in bioengineering and biotechnology · 2020Review
- Functional cardiac fibroblasts derived from human pluripotent stem cells via second heart field progenitors.Nature communications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeDemonstrate a novel manufacturing method to generate extracellular matrix scaffolds from cardiac fibroblasts (CF-ECM) as a therapeutic mesenchymal stem cell-transfer device. MATERIALS AND
methodsRat CF were cultured at high-density (~1.6×10
resultsCF-ECM scaffolds are composed of fibronectin (82%), collagens type I (13%), type III (3.4%), type V (0.2%), type II (0.1%) elastin (1.3%) and 18 non-structural bioactive molecules. Scaffolds remained intact on the mouse heart for 48 hours without the use of sutures or glue. Identified hEMSCs were distributed from the epicardium to the endocardium.
conclusionsHigh density cardiac fibroblast culture can be used to generate CF-ECM scaffolds. CF-ECM scaffolds seeded with hEMSCs can be maintained on the heart without suture or glue. hEMSC are successfully delivered throughout the myocardium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.